The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Correlation of pathogenic POLE mutations with clinical benefit to immune checkpoint inhibitor therapy.
 
Benjamin Garmezy
No Relationships to Disclose
 
Jinesh S. Gheeya
No Relationships to Disclose
 
Kyaw Zin Thein
No Relationships to Disclose
 
Patrick Glen Pilie
Patents, Royalties, Other Intellectual Property - Patent Pending- biomarker
 
Wanlin Wang
No Relationships to Disclose
 
Jordi Rodon Ahnert
Consulting or Advisory Role - Bayer; Certara Inc; Certara Inc; Ellipses Pharma; iOncologi; Kelun; Merck Sharp & Dohme; Peptomyc; Pfizer; Roche/Genentech; Spectrum Pharmaceuticals
Research Funding - Bayer; Novartis
 
Kenna Rael Shaw
Consulting or Advisory Role - Guidepoint Global
Research Funding - Guardant Health (Inst); Philips Healthcare (Inst); Tempus (Inst)
 
Funda Meric-Bernstam
Employment - MD Anderson Cancer Center
Honoraria - Dialectica; Sumitomo Group
Consulting or Advisory Role - Aduro Biotech; Clearlight Diagnostics; DarwinHealth; Debiopharm Group; eFFECTOR Therapeutics; Genentech; IBM; IBM; Immunomedics; Inflection Biosciences; Mersana; Origimed; PACT Pharma; Pieris Pharmaceuticals; Roche; Samsung Bioepis; Seagen; Silverback Therapeutics; Spectrum Pharmaceuticals; Xencor
Speakers' Bureau - Chugai Pharma
Research Funding - Abbvie (Inst); Aileron Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (I); Calithera Biosciences (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); eFFECTOR Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Guardant Health (Inst); Jounce Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PUMA Biotechnology (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Beth Israel Deaconess Medical Center; Seagen; Taiho Pharmaceutical
 
Timothy A Yap
Consulting or Advisory Role - Aduro Biotech; Almac Diagnostics; AstraZeneca; Atrin Pharmaceuticals; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Clovis Oncology; Cybrexa Therapeutics; EMD Serono; Ignyta; Janssen; Merck; Pfizer; Roche; Seagen; Tesaro; Vertex
Research Funding - AstraZeneca; Bayer; Constellation Pharmaceuticals; Jounce Therapeutics; Kyowa Hakko Kirin; Lilly; Pfizer; Seagen; Tesaro; Vertex
Patents, Royalties, Other Intellectual Property - MD Anderson Cancer Center holds the intellectual property rights to IACS-010759 and its designated use. (Inst)
Travel, Accommodations, Expenses - Atrin Pharmaceuticals; Calithera Biosciences; EMD Serono; Leidos Biomedical Research; Lilly; Pfizer; Tesaro